MetaCap

Regeneron Pharmaceuticals (REGN) vs Vertex Pharmaceuticals (VRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Regeneron Pharmaceuticals (REGN) has outperformed Vertex Pharmaceuticals (VRTX) over the past year, gaining 21.8% versus a gain of 20.7%. Over five years, VRTX leads with a +180.5% price change compared with +43.1% for REGN. Vertex Pharmaceuticals is the larger company by market cap ($130.58 billion vs $95.24 billion), about 1.4 times the size.

On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (12.8x vs 25.9x for Vertex Pharmaceuticals). Regeneron Pharmaceuticals pays a dividend yielding 0.40%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 31.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

REGN+21.80%VRTX+20.68%
+34%+5%-23%
Nov 21, 20251 yearNov 20, 2026
REGN+41.06%VRTX+181.62%
+217%+90%-36%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

REGN versus VRTX key metrics
MetricREGNVRTX
Share price$920.69$515.02
Market cap$95.24B$130.58B
1-day change-0.19%-1.08%
YTD return+19.28%+13.60%
1-year return+21.80%+20.68%
5-year return+43.11%+180.53%
P/E ratio (TTM)20.3533.14
Forward P/E12.8525.86
EPS (TTM)$45.24$15.54
Dividend yield0.40%0.00%
Annual dividend$3.70$0.00
Revenue (latest FY)$14.34B$12.00B
Revenue growth (YoY)+0.99%+8.90%
Net income (latest FY)$4.50B$3.95B
Gross margin—86.24%
Operating margin24.95%34.77%
Net margin31.41%32.94%
52-week high$991.73$568.67
52-week low$591.52$412.27
Distance from 52-week high-7.16%-9.43%
Analyst consensusbuybuy
Avg. price target upside+7.64%+15.60%
Average volume805.45K1.25M
Shares outstanding101.63M253.54M
Employees15,4106,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Vertex Pharmaceuticals trades at a higher earnings multiple (33.1x vs 20.4x trailing P/E).
  • Vertex Pharmaceuticals grew revenue faster in its latest fiscal year (+8.90% vs +0.99%).

About Regeneron Pharmaceuticals

REGN stock →

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees

About Vertex Pharmaceuticals

VRTX stock →

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees

REGN vs VRTX FAQ

Which is bigger, Regeneron Pharmaceuticals or Vertex Pharmaceuticals?

Vertex Pharmaceuticals (VRTX) is larger, with a market capitalization of $130.58B compared with $95.24B for Regeneron Pharmaceuticals (REGN).

Which stock has performed better over the past year, REGN or VRTX?

REGN returned +21.80% over the past 12 months, compared with +20.68% for VRTX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, REGN or VRTX?

REGN has the lower trailing P/E at 20.4, versus 33.1 for VRTX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Regeneron Pharmaceuticals or Vertex Pharmaceuticals?

Regeneron Pharmaceuticals pays a dividend yielding 0.40%, while Vertex Pharmaceuticals does not currently pay a regular dividend.

Are Regeneron Pharmaceuticals and Vertex Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons